BridgeBio's Infigratinib Shows Broader Benefits in Achondroplasia Trial
Event summary
- BridgeBio's oral infigratinib demonstrated favorable trends in sleep apnea and otitis media reduction in the Phase 3 PROPEL 3 trial for achondroplasia.
- The treatment stabilized sleep apnea measures and reduced ear infection rates by 38% compared to placebo.
- Sustained improvements in growth and body proportionality were observed over three years with no new safety signals.
- BridgeBio submitted an NDA to the FDA and anticipates a U.S. launch in mid-2027.
The big picture
BridgeBio's infigratinib is positioned to become the first oral therapy for achondroplasia, addressing a significant unmet need in the treatment of genetic skeletal dysplasias. The favorable trial results and regulatory designations highlight the potential for a transformative impact on patient outcomes, positioning BridgeBio as a key player in the genetic conditions space. The anticipated U.S. launch in mid-2027 could mark a significant milestone in the treatment of achondroplasia, potentially expanding the company's market reach and therapeutic portfolio.
What we're watching
- Regulatory Approval
- Whether the FDA will approve oral infigratinib by mid-2027 and the potential impact of the Breakthrough Therapy Designation on the review process.
- Market Positioning
- How BridgeBio positions infigratinib as a best-in-class option for achondroplasia and its potential to address broader medical and functional impacts of skeletal dysplasia conditions.
- Long-term Efficacy
- The sustained efficacy and safety of infigratinib over extended treatment periods and its potential to address multiple complications associated with achondroplasia.